UroGen Pharma (URGN) Tops Q2 EPS by 14c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/27/2026

1. ORCL
2. ANT
3. SPY
4. META
5. FFAI
6. FFR
7. CART
8. LLY
9. TSLA
10. FICO

Go back to UroGen Pharma (URGN) Tops Q2 EPS by 14c

UroGen Pharma Reports Second Quarter 2020 Financial Results and Recent Corporate Developments

August 10, 2020 8:00 AM EDT

Received U.S. FDA Approval of Jelmyto®, the First and Only Non-Surgical Treatment for Patients with Low-Grade Upper Tract Urothelial Cancer (LG-UTUC)

Successfully Commenced Launch of Jelmyto on June 1st as Planned; Initial Commercial Performance Demonstrates Strong Execution

Announced Positive Complete Response and Durability Data of UGN-102 in Patients with Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC); On Track to Commence Pivotal Phase 3 Trial by Year End

Conference Call and Webcast to be Held Today at 8:30 AM ET

... More